Imunon, Inc. is a clinical-stage biotechnology company developing treatments using non-viral DNA technology. Its first modality, TheraPlas®, targets solid tumor treatment through immunological methods. The second modality, PlaCCine®, codes viral antigens to induce immunological responses and may serve as a platform for vaccine development in infectious diseases. The company operates in the solid tumor treatment and infectious disease vaccine markets.

Imunon Inc’s Comment on Sales, Marketing and Customers

IMNN's Stock Performance relative to it's Customers

IMNN's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Imunon Inc	7.69	0.50	-14.64	20
SUBTOTAL	0.00	0.00	0.00	-

Sources: Imunon Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Imunon Inc’s corporate clients.
For your research, we’ve provided 9 tables on Imunon Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.